Among the most employer-demanded SLP certifications for neuro outpatient; frequently required or preferred in job listings.
Patient experience weight 5
76/100
Patients report meaningful communication improvement; family-reported quality of life gains significant in PD.
Cash-pay viability weight 25
55/100
PD families regularly pay cash for LSVT when insurance limits hit; one of the more cash-friendly SLP credentials.
Pricing leverage weight 20
60/100
Branded, trademarked protocol commands premium pricing within SLP space.
Market differentiation weight 15
70/100
Strong consumer-recognizable brand within the Parkinson's community; defensible niche.
Owner leverage weight 15
65/100
Protocol is taught and staffable; LSVT-certified SLPs can deliver under a clinic brand.
Consumer demand weight 15
55/100
PD support groups and neurologists actively refer to LSVT providers.
Credential investment weight 10
50/100
Certification fee is meaningful (~$800+) and requires recertification.
Faculty recognition weight 25
60/100
Recognized as legitimate evidence-based protocol in SLP academia.
Scholarship signal weight 20
75/100
Strong publication pipeline from LSVT Global research team.
Teaching value weight 15
70/100
Standard teaching exemplar in PD/neuro SLP coursework.
Evidence depth weight 20
75/100
Multiple RCTs supporting efficacy in PD dysarthria.
Faculty demand weight 10
50/100
Useful but not commonly required in SLP faculty postings.
Credential investment weight 10
55/100
Moderate cost and time; reasonable academic ROI.
Sources · 47 on file
The citation library behind every score.
Evidence mix
RCT
15
32%
Case series
5
11%
Pilot/feasibility
3
6%
Systematic review
2
4%
Narrative review
2
4%
Meta-analysis
2
4%
Cohort study
1
2%
Study protocol
1
2%
Other
16
34%
Publication years94% since 2021
13
2020 last five years earlier2025
Librarian-reviewedLast reviewed 2025-1247 sources
01
Effects of Lee Silverman Voice Treatment‐BIG on Motor, Cognition, Mental Health, Occupational Performance, and Occupational Balance in Patients With Schizophrenia: A Single‐Subject Experimental Study
W.-H. Jang; S.-M. Seo; S.-H. Kim; C. Hilton · Occupational Therapy International · 2025
The PD COMM Process Evaluation: Describing Interventions and Implementation in a UK Pragmatic Randomised Controlled Trial of Speech and Language Therapy for People With Parkinson's-Related Dysarthria
A. Nicoll; M. C. Brady; P. Masterson-Algar; C. Burton; G. Beaton; S. Dickson; M. Caulfield; C. H. Smith; C. E. Clarke; N. Ives; S. Jowett; C. Rick; R. Woolley; C. M. Sackley · Int J Lang Commun Disord · 2025
The Acoustic Voice Quality Index (AVQI) in People with Parkinson's Disease Before and After Intensive Voice and Articulation Therapies: Secondary Outcome of a Randomized Controlled Trial
G. Moya-Galé; J. Spielman; L. A. Ramig; L. Campanelli; Y. Maryn · Journal of Voice · 2024
Behavioral Management of Respiratory/Phonatory Dysfunction for Dysarthria Associated With Neurodegenerative Disease: A Systematic Review
S. E. Perry; M. Troche; J. E. Huber; J. Curtis; B. Kiefer; J. Sevitz; Q. Dennard; J. Borders; J. R. Browy; A. Dakin; V. Gonzalez; J. Chapman; T. Wu; L. Katz; D. Britton · Am J Speech Lang Pathol · 2024
Show all 47 citationsShowing all 47 citations+35 moreCollapse
13
Narrative analysis in individuals with Parkinson's disease following intensive voice treatment: secondary outcome variables from a randomized controlled trial
A. E. Ramage; K. J. Greenslade; K. Cote; J. N. Lee; C. M. Fox; A. Halpern; L. O. Ramig · Front Hum Neurosci · 2024
The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT
C. M. Sackley; C. Rick; M. C. Brady; C. Burton; S. Jowett; S. Patel; R. Woolley; P. Masterson-Algar; A. Nicoll; C. H. Smith; Z. Abdali; N. Ives; G. Beaton; S. Dickson; R. Ottridge; H. Nankervis; C. E. Clarke · Health Technol Assess · 2024
Lee Silverman voice treatment versus NHS speech and language therapy versus control for dysarthria in people with Parkinson's disease (PD COMM): pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial
C. M. Sackley; C. Rick; M. C. Brady; R. Woolley; C. Burton; S. Patel; P. Masterson-Algar; A. Nicoll; C. H. Smith; S. Jowett; N. Ives; G. Beaton; S. Dickson; R. Ottridge; L. Sharp; H. Nankervis; C. E. Clarke · Bmj · 2024
Factors Associated With Treatment-Related Changes in Voice Volume in People With Multiple Sclerosis
V. Crispiatico; C. Baldanzi; M. Bertuletti; S. Grassi; F. Tedeschi; E. Groppo; M. Rovaris; D. Cattaneo; C. Vitali · International Journal of MS Care · 2023
Crowdsourced Perceptual Ratings of Voice Quality in People With Parkinson’s Disease Before and After Intensive Voice and Articulation Therapies: Secondary Outcome of a Randomized Controlled Trial
T. McAllister; C. Nightingale; G. Moya-Galé; A. Kawamura; L. O. Ramig · Journal of Speech, Language & Hearing Research · 2023
Telerehabilitation for Lee Silverman Voice Treatment (Tele-LSVT)-Loud on voice intensity and voice use in daily living in people with multiple sclerosis: A protocol for a feasibility and pilot randomized controlled study
C. Vitali; G. Fusari; C. Baldanzi; D. M. Cacciatore; V. Crispiatico; A. Carullo; M. Rovaris; D. Cattaneo; F. Baglio; S. Isernia · Digit Health · 2023
Intensive voice treatment (the Lee Silverman Voice Treatment [LSVT<sup>®</sup>LOUD]) for individuals with Wilson's disease and adult cerebral palsy: two case reports
E. Ertan; H. I. Gürvit; H. H. Hanağası; B. Bilgiç; M. A. Tunçer; C. Yılmaz · Logopedics Phoniatrics Vocology · 2022
The Impact of PD Check-In, a Model for Supported Self-Managed Maintenance of Speech on the Quality of Life of People with Parkinson's Disease: A Phase 1 Study
A. Finnimore; D. Theodoros; A. Rumbach · Brain Sci · 2022
PD Check-In: The development and trial of a supported self-management program for people with Parkinson's disease following intensive speech intervention
A. Finnimore; D. Theodoros; A. F. Rumbach · Int J Lang Commun Disord · 2022
Immediate and long-term effects of speech treatment targets and intensive dosage on Parkinson's disease dysphonia and the speech motor network: Randomized controlled trial
S. Narayana; C. Franklin; E. Peterson; E. J. Hunter; D. A. Robin; A. Halpern; J. Spielman; P. T. Fox; L. O. Ramig · Hum Brain Mapp · 2022
Evaluation of an intensive voice treatment to reduce anterior drooling in children with cerebral palsy: Protocol for a concurrent multiple-baseline, single case experimental design study
M. McInerney; C. Imms; P. N. Carding; D. S. Reddihough · Contemp Clin Trials Commun · 2021
Effects of Lee Silverman Voice Treatment (LSVT LOUD) on Swallowing in Patients with Progressive Supranuclear Palsy: A Pilot Study
S. Nozaki; M. Fujiu-Kurachi; T. Tanimura; K. Ishizuka; E. Miyata; S. Sugishita; T. Imai; M. Nishiguchi; M. Furuta; S. Yorifuji · Prog Rehabil Med · 2021
Single Word Intelligibility of Individuals with Parkinson's Disease in Noise: Pre-Specified Secondary Outcome Variables from a Randomized Control Trial (RCT) Comparing Two Intensive Speech Treatments (LSVT LOUD vs. LSVT ARTIC)
G. Schulz; A. Halpern; J. Spielman; L. Ramig; I. Panzer; A. Sharpley; K. Freeman · Brain Sci · 2021
Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial
S. Scobie; S. Jowett; T. Lambe; S. Patel; R. Woolley; N. Ives; C. Rick; C. Smith; M. C. Brady; C. Clarke; C. Sackley · Pilot Feasibility Stud · 2021
A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial
C. M. Sackley; C. Rick; P. Au; M. C. Brady; G. Beaton; C. Burton; M. Caulfield; S. Dickson; F. Dowling; M. Hughes; N. Ives; S. Jowett; P. Masterson-Algar; A. Nicoll; S. Patel; C. H. Smith; R. Woolley; C. E. Clarke; P. C. C. Group · Trials · 2020
Lee Silverman Voice Treatment for dysarthria in patients with Parkinson's disease: a systematic review and meta-analysis
F. Yuan; X. Guo; X. Wei; F. Xie; J. Zheng; Y. Huang; Z. Huang; Z. Chang; H. Li; Y. Guo; J. Chen; J. Guo; B. Tang; B. Deng; Q. Wang · Eur J Neurol · 2020